Navigation Links
PAREXEL International Expands Relationship with Synchron Research in India and Divests Bioanalytical Laboratory in France
Date:3/27/2008

t research organization in India. In 2006, PAREXEL expanded its relationship with Synchron by acquiring a majority stake of Synchron's clinical trials business operations in Bangalore, India, and a minority equity interest in Synchron's Ahmedabad, India clinical pharmacology business. In 2007, PAREXEL opened an office in Hyderabad, India to offer clients a wide range of clinical research and data management services.

PAREXEL has clinical pharmacology units in the United States, United Kingdom, Europe, and South Africa. The units provide bioanalytical services, data management, biostatistics, medical writing, and pharmacokinetic services for early phase clinical studies. PAREXEL's clinical pharmacology experts have a broad range of therapeutic experience, including central nervous system, cardiovascular, respiratory, metabolism/endocrine, and oncology.

About the Company

PAREXEL International Corporation is a leading global bio/pharmaceutical services organization, providing a broad range of knowledge-based contract research, medical communications and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries.

Committed to providing solutions that expedite time-to-market and peak- market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 64 locations throughout 51 countries around the world, and has over 7,320 employees. For more information about PAREXEL International visit http://www.PAREXEL.com.

This release contains
'/>"/>

SOURCE PAREXEL International Corporation
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4

Related biology technology :

1. PAREXEL Announces Date of Third Quarter Fiscal Year 2008 Earnings Release and Conference Call
2. PAREXEL Appoints Leading Biopharmaceutical Marketing Expert Jacque Fisher to Medical Communications Services Executive Team
3. PAREXEL International to Present at Lehman Brothers 11th Annual Global Healthcare Conference
4. PAREXEL International to Present at Raymond James 29th Annual Institutional Investors Conference
5. PAREXEL to Present Leading Insights Regarding Key Industry Topics at 20th Annual Drug Information Association EuroMeeting
6. PAREXEL International Announces 2-For-1 Stock Split
7. PAREXEL Reports Second Quarter Fiscal Year 2008 Financial Results
8. PAREXEL Names Biopharmaceutical Industry Executive Eduard E. Holdener to Board of Directors
9. PAREXEL Announces Date of Second Quarter Fiscal Year 2008 Earnings Release and Conference Call
10. PAREXEL Appoints Charles A. Stevens as Vice President/General Manager of Health Policy and Strategic Reimbursement and Strengthens Capabilities
11. PAREXEL Reports First Quarter Fiscal Year 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... June 18, 2013 China Cord Blood Corporation ... China,s leading provider of cord blood collection, laboratory testing, ... today announced its preliminary unaudited financial results for the ... ended March 31, 2013. Fourth Quarter ... fourth quarter of fiscal 2013 increased by 33.3% to ...
(Date:6/18/2013)... PA (PRWEB) June 18, 2013 Demanding ... Ball Lenses engineered of synthetic Sapphire and Glass Ball ... sizes from Swiss Jewel Company , of Philadelphia ... by expanding and collimating the light beams without the ... optical clarity and natural durability (9 mohs) make it ...
(Date:6/18/2013)... RegeneCure announced today the start of a ... (GBR) Dental Membrane as a bone stimulating aid for patients ... patients have a tooth replaced with a dental implant is ... Consequently there is often a need to support the implant ... bone substitute material, in turn, needs to be held in ...
(Date:6/18/2013)... , June 18, 2013  AMRI (NASDAQ: ... Burlington, Mass. , site has ... Enforcement Administration (DEA) registration to handle Schedule 2 ... DEA,s acknowledgement of Burlington,s ... and documentation. (Logo: http://photos.prnewswire.com/prnh/20120229/NY61160LOGO ) ...
Breaking Biology Technology:China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 2China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 3China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 4China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 5China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 6China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 7China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 8China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 9China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 10China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 11China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 12China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 13Swiss Jewel Introduces the Crown Jewels of Fiber-Optic Connectors 2RegeneCure Starts Clinical Study Using Polymeric Bone Stimulating Membrane for Dental Implants 2RegeneCure Starts Clinical Study Using Polymeric Bone Stimulating Membrane for Dental Implants 3AMRI Burlington Receives DEA Approval to Handle Controlled Substances 2
... 31 Savient,Pharmaceuticals, Inc. (Nasdaq: SVNT ) today ... and Drug Administration (FDA) seeking approval to,market pegloticase in ... review. Savient,s filing includes data from both the six-month,placebo ... from the Open,Label Extension (OLE) study. The data set ...
... 31 /Xinhua-PRNewswire/ -- Sundia MediTech,Company, a Shanghai-based drug ... this year,s Deloitte Technology,Fast 50 China award, and ... 50 China Program was announced today in Shenzhen, ... 50 Program started in 1995 in San Jose. ...
... than a dozen employers in health care, employment continued to increase in ... like no one was searching for those new jobs. , ... Seattle, ... care field, with an average of 30,000 jobs created each month. Even ...
Cached Biology Technology:Savient Submits Biologics License Application (BLA) for pegloticase 2Savient Submits Biologics License Application (BLA) for pegloticase 3Savient Submits Biologics License Application (BLA) for pegloticase 4Sundia MediTech Ranked #16 in Deloitte Technology Fast 50 China 2The MedZilla Report: September 2008 Employment Outlook for Biotech/Pharma/Health 2The MedZilla Report: September 2008 Employment Outlook for Biotech/Pharma/Health 3
(Date:6/18/2013)... It is estimated that between 5% and 10% of ... is to say that these tumours are attributable to ... BRCA1 or BRCA2. In patients with these mutations, PARP ... encouraging results that make them a new option for ... the latest studies indicate that a fraction of these ...
(Date:6/18/2013)... LA, London (18 June 2013). A team of internationally ... by Dr Sarah Ellis from the University of Lincoln, ... Clinic, Wisconsin, U.S.A. were invited by the International Society ... Feline Practitioners (AAFP) to compile guidelines for veterinarians, owners ... the environmental needs of the domestic cat. The new ...
(Date:6/17/2013)... MA Women in the U.S. exposed to high levels ... likely to have a child with autism as women who ... study from Harvard School of Public Health (HSPH). It is ... and air pollution across the U.S. , "Our findings raise ... the women in our study lived in areas where risk ...
Breaking Biology News(10 mins):An article in 'Cell' reveals a new resistance mechanism to chemotherapy in breast and ovarian cancer 2Feline behavior experts release guidelines to improve the welfare of cats 2Exposure to high pollution levels during pregnancy may increase risk of having child with autism 2
... April 14, 2011 -- The number of couples struggling with ... assisted reproductive technologies, like in vitro fertilization (IVF), to get ... increase the risk of multiple pregnancies (i.e., twins or triplets), ... Twins and triplets are likely to be born prematurely, ...
... 2011 Ceelox, Inc. (OTCBB: CELO) announced today that ... to cloud applications using biometrics. Ceelox ID Online® utilizes ... an Internet server-based biometric software application. This enables users ... credentials, i.e. user name and password, compromised or stolen ...
... The following highlights summarize research papers that have been ... 1. Little Ice Age resulted from more than just ... measure of the amount of light the Sun puts out, ... especially when TSI is notably higher or lower than its ...
Cached Biology News:New study finds stronger regulations of in vitro fertilization may save lives 2Ceelox Provides Biometric Identity Access to Cloud Applications 2Ceelox Provides Biometric Identity Access to Cloud Applications 3AGU journal highlights -- April 13, 2011 2AGU journal highlights -- April 13, 2011 3AGU journal highlights -- April 13, 2011 4AGU journal highlights -- April 13, 2011 5AGU journal highlights -- April 13, 2011 6AGU journal highlights -- April 13, 2011 7
...
BD BioCoat Collagen IV 35 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of mouse collagen type IV....
... are designed for sequencing inserts cloned into ... or T3 RNA polymerase promoters, or lambda ... at a concentration of 0.1 µg/µl in ... DNA sequencing reactions using SequiTherm™ EXCEL™ II ...
BD BioCoat Matrigel Matrix 35 mm Culture Dishes Coating : BD MatrigelTM Basement Membrane Matrix ,Surface : ECM/attachment factors ,Surface area : 9.6 cm2 ,Dim nominal : 35 mm x 10 mm ,Vo...
Biology Products: